Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Construction in Progress (2019 - 2022)

Eton Pharmaceuticals' Construction in Progress history spans 3 years, with the latest figure at $12000.0 for Q4 2022.

  • For Q4 2022, Construction in Progress changed N/A year-over-year to $12000.0; the TTM value through Dec 2022 reached $12000.0, changed N/A, while the annual FY2022 figure was $12000.0, N/A changed from the prior year.
  • Construction in Progress for Q4 2022 was $12000.0 at Eton Pharmaceuticals, roughly flat from $12000.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $873000.0 in Q1 2019 and bottomed at $1000.0 in Q3 2020.
  • The 3-year median for Construction in Progress is $9000.0 (2019), against an average of $130571.4.
  • The largest YoY upside for Construction in Progress was 66.67% in 2020 against a maximum downside of 99.54% in 2020.
  • A 3-year view of Construction in Progress shows it stood at $9000.0 in 2019, then plummeted by 88.89% to $1000.0 in 2020, then surged by 1100.0% to $12000.0 in 2022.
  • Per Business Quant, the three most recent readings for ETON's Construction in Progress are $12000.0 (Q4 2022), $12000.0 (Q1 2022), and $1000.0 (Q3 2020).